Kenneth Allen Myszkowski sold $893k of ARWR
Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC.. 45,167 shares at an average of $19.77, traded Jan 6, 2025, filed Jan 7, 2025.
Score components
- +22RoleCFO
- +24Trade size$893k at market
- 0Share of holdings soldSold 9.0% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +4.1%, 3m -49.2%, 6m -10.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-000805, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 4, 2025 | AGrant or award Common Stock10b5-1 | +100,000 | $0.00 | $0 | 500,600 | Jan 7, 2025 |
| Jan 6, 2025 | SOpen-market sale Common Stock10b5-1 | -17,765 | $19.68 | $350k | 482,835 | Jan 7, 2025 |
| Jan 6, 2025 | SOpen-market sale Common Stock10b5-1 | -9,402 | $20.10 | $189k | 473,433 | Jan 7, 2025 |
| Jan 7, 2025 | SOpen-market sale Common Stock10b5-1 | -8,000 | $19.70 | $158k | 465,433 | Jan 7, 2025 |
| Jan 7, 2025 | SOpen-market sale Common Stock10b5-1 | -10,000 | $19.69 | $197k | 455,433 | Jan 7, 2025 |
Related signals
Other insiders at ARROWHEAD PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | ARROWHEAD PHARMACEUTICALS, INC. | Adeoye Y Olukotun director | $174k 2,000 shares | -6% | |
| 48Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Michael S Perry director | $1.0M 11,600 shares | -9% | |
| 8Weak | ARROWHEAD PHARMACEUTICALS, INC. | Hongbo Lu director | $228k 2,970 shares | -5% | |
| 34Weak | ARROWHEAD PHARMACEUTICALS, INC. | Daniel Joseph Apel Chief Financial Officer | $934k 13,095 shares | -7% | |
| 25Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $750k 10,000 shares | -4% | |
| 15Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $642k 10,000 shares | -4% | |
| 43Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $872k 13,187 shares | -0% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Patrick O'Brien COO | $3.1M 49,493 shares | -9% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $2.5M 40,164 shares | -19% | |
| 30Weak | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $3.6M 51,726 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.